QMQingyong Meng

Qingyong Meng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qingyong Meng has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anti‐TSNARE1 IgG plasma levels differ by sex in patients with schizophrenia in a Chinese population

    by Chan Li, Ruth Whelan, Hua Yang, Yaling Jiang, Chaosen Qiu, Qingyong Meng, Jun Wei

    It was recently reported that levels of plasma IgG antibodies against peptide antigens derived from proteins encoded by schizophrenia‐associated genes are altered in individuals with schizophrenia treated with antipsychotics. This study aimed to replicate the initial finding in antipsychotic‐naïve patients with first‐episode schizophrenia and to explore the possible mechanism by which immune tolerance of B cells may be altered in this disease. A total of 408 case–control plasma samples were collected for analysis of circulating IgG antibodies against fragments derived from TCF4, TSNARE1, ZNF804A, TRANK1, ERCC4, DPYD and CD25 using an in‐house ELISA. The Mann–Whitney U‐test revealed that patients with schizophrenia had a significant change in plasma anti‐TSNARE1 and anti‐CD25 IgG levels; male patients mainly contributed to the increased levels of anti‐TSNARE1 IgG and anti‐CD25 IgG. Receiver operating characteristic (ROC) curve analysis revealed that the anti‐TSNARE1 IgG assay had an area under the ROC curve of 0.625 with a sensitivity of 15.7% and a specificity of 95.2%. Work on a B‐cell model revealed that TRANK1‐derived antigen treatments could enhance the proportions of CD83+ cells and apoptotic B cells when compared with TSNARE1‐derived antigen and vehicle treatment. We conclude that there is a gender difference in autoimmune responses in schizophrenia and suggest that anti‐TSNARE1 IgG may be indicative of schizophrenia in a subgroup of male patients.


  • A study of anti-gliadin antibodies in first-episode patients with schizophrenia among a Chinese population

    by Hua Yang, Yaling Jiang, Zhenjian Chen, Jingqing Wu, Chaosen Qiu, Qingyong Meng


  • Open Access

    Detection of circulating natural antibodies to inflammatory cytokines in type-2 diabetes and clinical significance

    by Weiyi Cai, Cailing Qiu, Hongyu Zhang, Xiangyun Chen, Xuan Zhang, Qingyong Meng, Jun Wei

    Inflammatory cytokines have been demonstrated to be involved in developing insulin resistance and type-2 diabetes (T2D). Natural antibodies in the circulation have protective effects on common diseases in humans. The present study was thus designed to test the hypothesis that natural antibodies against inflammatory cytokines could be associated with T2D. An enzyme-linked immunosorbent assay (ELISA) was developed in-house to detect plasma IgG against peptide antigens derived from interleukin 1α (IL1α), IL1β, IL6, IL8 and tumor necrosis factor-α (TNF-α) in 200 patients with T2D and 220 control subjects. Binary regression showed that compared with control subjects, T2D patients had a decreased level of plasma anti-IL6 IgG (adjusted r 2=0.034, p=0.0001), anti-IL8 IgG (adjusted r 2=0.021, p=0.002) and anti-TNF-α IgG (adjusted r 2=0.017, p=0.003). Female patients mainly contributed to decreased levels of anti-IL6 IgG (adjusted r 2=0.065, p=0.0008) and anti-IL8 IgG (adjusted r 2=0.056, p=0.003), while male patients mainly contributed to decreased anti-TNF-α IgG levels (adjusted r 2=0.024, p=0.005). ROC curve analysis revealed a sensitivity of 16.5% against specificity of 95.5% for anti-IL6 IgG assay and a sensitivity of 19.5% against specificity of 95.9% for anti-IL8 IgG assay. Glycated hemoglobin levels measured after 6-month glucose-lowering treatment appeared to be inversely correlated with plasma anti-IL1α IgG (r=-0.477, df=17, p=0.039) and anti-IL6 IgG (r=-0.519, df=17, p=0.023) although such correlation failed to survive the Bonferroni correction. Deficiency of natural IgG against inflammatory cytokines is likely to be a risk factor for T2D development and detection of such antibodies may be useful for personalized treatment of the disease.


  • Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer

    by Weili Wang, Wen Zhong, Cairen Chen, Qingyong Meng, Jun Wei

    Background: Our previous studies revealed that concentrations of circulating antibodies to annexin A1 (ANXA1) and forkhead-box P3 (FOXP3) increased significantly in patients with non-small cell lung cancer (NSCLC). This study was thus undertaken to replicate our initial findings with different sample sets. Patients and Methods: Antibodies were tested in 108 patients with NSCLC and 216 controls, who were divided into the discovery (49 vs. 108) and validation (60 vs. 108) group based on the time of enrolment. Results: Analysis of the discovery group showed a significant increase in circulating anti-ANXA1 IgG levels in the patient group compared with the control group (p=0.005) but the validation group simply exhibited a trend toward an increase in IgG levels in NSCLC (p=0.238), generating a combined p-value of 0.009. Conclusion: The findings of this study support the notion that circulating IgG antibodies to ANXA1 could be used as a biomarker for early diagnosis of NSCLC but failed to replicate such findings for FOXP3.


  • Open Access

    Further study of circulating IgG antibodies to CD25‐derived peptide antigens in nonsmall cell lung cancer

    by Cairen Chen, Weili Wang, Qingyong Meng, Ning Wu, Jun Wei

    A recent study reported that circulating antibodies to CD25‐derived peptide antigens were significantly higher in patients with nonsmall cell lung cancer (NSCLC) than control subjects. The present study was, thus, undertaken to replicate the initial finding with different sample sets. An in‐house ELISA was applied to determine circulating IgG antibodies to linear peptide antigens derived from CD25. A total of 111 patients with NSCLC and 216 control subjects were recruited and divided into the discovery sample (51 vs 108) and the validation sample (60 vs 108) based on the time of sampling. Student's t test showed that circulating anti‐CD25 IgG levels were significantly higher in the patient group than the control group (t = 2.23, P = 0.027) and the validation sample replicated this finding (t = 3.31, P = 0.0012), generating a combined P value of 0.0004 (χ2 = 20.8, df = 4). Fisher's combining probability revealed that patients with stage IV NSCLC had a significant increase in anti‐CD25 IgG levels compared with control subjects (χ2 = 22.1, df = 4, P = 0.0002) but those with the other three stages did not. This study suggests that circulating anti‐CD25 IgG antibodies may have prognostic rather than early diagnostic values for lung cancer.


  • Investigation of circulating antibodies to ANXA1 in breast cancer

    by Yile Huang, Cong Zhang, Cairen Chen, Shilong Sun, He Zheng, Shuli Wan, Qingyong Meng, Yubin Chen, Jun Wei